Normative Database of Healthy Subject Vascular Density Using Spectralis Heidelberg® Optical Coherence Tomography Angiography

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Optical coherence tomography angiography (OCT-A) is a determinant progress to study retinal and choroidal vasculature without using a dye injection. OCT-A yields interesting results in different pathologies such as diabetes mellitus, age-related macular degeneration, hypertension blood pressure, particularly by affecting vascular density. Normative database are necessary to compare OCT-A parameters between patients and controls. However, OCT-A devices from different manufactures may give different values for the same subject. It seems to be obvious that each OCT-A device should have its own normative database. In the literature, OCT-A normative databases are developing using different types of devices, but none is available for Heidelberg OCT-A in Caucasians. The purpose of this project is to create a normative database of retinal microvascularisation using Spectralis Heidelberg optical coherence tomography angiography (OCT-A) ® in normal controls.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Voluntary adult subjects or legal representative consenting for minor or subjects under protection

• Intra ocular pression ≤ 21mmHg

• Spherical refraction comprised between - 6 D and +6 D and/or axial length between 21 and 26mm

• Patient affiliated to social security system

Locations
Other Locations
France
Amiens University Hospital
RECRUITING
Amiens
Contact Information
Primary
Ha-Chau TRAN, Pr
tran.chau@chu-amiens.fr
03 22 08 92 00
Time Frame
Start Date: 2023-06-12
Estimated Completion Date: 2026-09
Participants
Target number of participants: 200
Treatments
Experimental: healthy subject vascular density
Sponsors
Collaborators: Hôpital Saint Vincent de Paul, Lille, GHPSO de Creil
Leads: Centre Hospitalier Universitaire, Amiens

This content was sourced from clinicaltrials.gov